[go: up one dir, main page]

LT2833884T - Ccr3-inhibitorių panaudojimas - Google Patents

Ccr3-inhibitorių panaudojimas

Info

Publication number
LT2833884T
LT2833884T LTEP13713199.1T LT13713199T LT2833884T LT 2833884 T LT2833884 T LT 2833884T LT 13713199 T LT13713199 T LT 13713199T LT 2833884 T LT2833884 T LT 2833884T
Authority
LT
Lithuania
Prior art keywords
ccr3
inhibitors
Prior art date
Application number
LTEP13713199.1T
Other languages
English (en)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Alkahest, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2833884(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkahest, Inc. filed Critical Alkahest, Inc.
Publication of LT2833884T publication Critical patent/LT2833884T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
LTEP13713199.1T 2012-04-03 2013-04-02 Ccr3-inhibitorių panaudojimas LT2833884T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
LT2833884T true LT2833884T (lt) 2020-09-10

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13713199.1T LT2833884T (lt) 2012-04-03 2013-04-02 Ccr3-inhibitorių panaudojimas

Country Status (28)

Country Link
US (5) US20130261153A1 (lt)
EP (3) EP2833884B1 (lt)
JP (2) JP2015512432A (lt)
KR (4) KR20200044988A (lt)
CN (2) CN104220073A (lt)
AU (1) AU2013245027B2 (lt)
BR (1) BR112014023795B1 (lt)
CA (1) CA2869269C (lt)
CL (1) CL2014002523A1 (lt)
CY (1) CY1123222T1 (lt)
DK (1) DK2833884T3 (lt)
EA (1) EA032263B1 (lt)
ES (2) ES2987267T3 (lt)
HR (1) HRP20201165T1 (lt)
HU (1) HUE051648T2 (lt)
IL (1) IL234262A (lt)
IN (1) IN2014DN06989A (lt)
LT (1) LT2833884T (lt)
MX (1) MX2014011786A (lt)
NZ (1) NZ628882A (lt)
PH (1) PH12014502239A1 (lt)
PL (1) PL2833884T3 (lt)
PT (1) PT2833884T (lt)
RS (1) RS60665B1 (lt)
SI (1) SI2833884T1 (lt)
SM (1) SMT202000499T1 (lt)
WO (1) WO2013149986A1 (lt)
ZA (1) ZA201406082B (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
EP3449866B1 (en) 2016-11-24 2021-10-20 Kirishima Seiko Co., Ltd. Orthodontic appliance
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
EP4245295A3 (en) * 2017-04-05 2023-11-01 Alkahest, Inc. Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
KR20200067859A (ko) * 2017-10-13 2020-06-12 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물
MX2020011114A (es) 2018-05-15 2021-01-29 Alkahest Inc Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.
EA202190463A1 (ru) * 2018-09-26 2021-06-29 Алкахест, Инк. Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
CA3180401A1 (en) * 2020-06-11 2021-12-16 Bartosz SIKORSKI Methods of improving retina-associated disease outcome using ccr3-inhibitors
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
GB2361704C (en) * 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
WO2010138591A1 (en) * 2009-05-26 2010-12-02 University Of Kentucky Research Foundation Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
SMT202000499T1 (it) 2020-11-10
RS60665B1 (sr) 2020-09-30
PL2833884T3 (pl) 2020-11-02
EP4389217A2 (en) 2024-06-26
EA201401083A1 (ru) 2015-03-31
CL2014002523A1 (es) 2015-01-23
EP4389217A3 (en) 2024-08-28
ES2811554T3 (es) 2021-03-12
IN2014DN06989A (lt) 2015-04-10
BR112014023795B1 (pt) 2021-09-08
JP2018080183A (ja) 2018-05-24
CA2869269C (en) 2020-06-30
CN110384699A (zh) 2019-10-29
CY1123222T1 (el) 2021-10-29
BR112014023795A2 (lt) 2017-06-20
PH12014502239A1 (en) 2014-12-15
US20150099783A1 (en) 2015-04-09
SI2833884T1 (sl) 2020-10-30
ES2987267T3 (es) 2024-11-14
JP2015512432A (ja) 2015-04-27
WO2013149986A1 (en) 2013-10-10
DK2833884T3 (da) 2020-08-10
EA032263B1 (ru) 2019-05-31
KR20200044988A (ko) 2020-04-29
EP2833884B1 (en) 2020-05-20
KR20220132012A (ko) 2022-09-29
CA2869269A1 (en) 2013-10-10
US20170319567A1 (en) 2017-11-09
NZ628882A (en) 2016-05-27
BR112014023795A8 (pt) 2017-10-10
AU2013245027B2 (en) 2017-10-12
EP2833884A1 (en) 2015-02-11
HRP20201165T1 (hr) 2020-12-11
KR20140144200A (ko) 2014-12-18
ZA201406082B (en) 2019-01-30
EP3763369B1 (en) 2024-02-28
HUE051648T2 (hu) 2021-03-29
US20160081998A1 (en) 2016-03-24
CN104220073A (zh) 2014-12-17
AU2013245027A1 (en) 2014-09-11
EP3763369A1 (en) 2021-01-13
KR20210063481A (ko) 2021-06-01
IL234262A (en) 2017-10-31
MX2014011786A (es) 2014-12-05
US20200375971A1 (en) 2020-12-03
US20130261153A1 (en) 2013-10-03
PT2833884T (pt) 2020-08-26

Similar Documents

Publication Publication Date Title
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HRP20171401T1 (hr) Jednokratni uređaj za anastomozu za obrezivanje
HK1212701A1 (zh) 恩雜魯胺製劑
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
ZA201406082B (en) Use of ccr3-inhibitors
HK1209767A1 (en) Purification of iduronate-2-sulfatase -2-
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
GB201216800D0 (en) Novel use
IL236312A0 (en) Preparation of 18f-flucyclobin
HK1201270A1 (en) Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5--
IL239245A0 (en) A new use of Eclidenium
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
GB201212463D0 (en) Novel use
TWM433525U (en) Structure of calorifier
GB201206393D0 (en) Use
GB201217666D0 (en) Construction of surfaces
GB201202256D0 (en) Novel use
GB201213726D0 (en) Novel compounds and their use
GB201209895D0 (en) Use of a composition
GB201220595D0 (en) Keysafe application
GB201207075D0 (en) New compounds and uses
GB201206973D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses